<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39554473</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-6973</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Infection and drug resistance</Title><ISOAbbreviation>Infect Drug Resist</ISOAbbreviation></Journal><ArticleTitle>Clinical Features of Patients with COVID-19 Recurrence During Hospitalization in the Omicron Variant Surge.</ArticleTitle><Pagination><StartPage>5011</StartPage><EndPage>5015</EndPage><MedlinePgn>5011-5015</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IDR.S485976</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Repeat positive results for SARS-CoV-2 by antigen detection test/RT-PCR in recovered COVID-19 patients were not very rare even when omicron variants became dominant, but the clinical features of patients with recurrent COVID-19 during hospitalization are still unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The clinical characteristics of patients with recurrent COVID-19 during hospitalization were retrospectively investigated from January 2023 to December 2023.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Recurrence of COVID-19 was found in 7 of 275 (2.5%) patients during hospitalization. Their mean age was 80.3 (74-89) years, and 4 of 7 (57.1%) patients were hospitalized on the hematology ward with B cell/non-Hodgkin lymphoma. These 4 lymphoma patients had been vaccinated, but the other 3 patients hospitalized on the emergency ward and the neurology ward had not been vaccinated. Of the 7 patients, 6 (85.7%) were initially treated with remdesivir (RDV), but only 3 patients were re-treated with RDV, and the other 4 patients were successfully re-treated with oral 3C-like protease inhibitors, such as ensitrelvir (ESV) and nirmatrelvir/ritonavir (N/R).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">These data suggest that COVID-19 recurrence was found in patients with hematological disorders, such as lymphoma, and/or patients with no vaccination history. However, these patients were treated successfully by re-administration of anti-SARS-CoV-2 agents, including ESV and N/R.</AbstractText><CopyrightInformation>© 2024 Seki et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seki</LastName><ForeName>Masafumi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5414-8148</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubosawa</LastName><ForeName>Chie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ono</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamoshita</LastName><ForeName>Fumitaka</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Atsuko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsutake</LastName><ForeName>Kotaro</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2429-511X</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Drug Resist</MedlineTA><NlmUniqueID>101550216</NlmUniqueID><ISSNLinking>1178-6973</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-CD20+ B cell depletion</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">ensitrelvir</Keyword><Keyword MajorTopicYN="N">nirmatrelvir/ritonavir</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39554473</ArticleId><ArticleId IdType="pmc">PMC11568766</ArticleId><ArticleId IdType="doi">10.2147/IDR.S485976</ArticleId><ArticleId IdType="pii">485976</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa478</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa478</ArticleId><ArticleId IdType="pmc">PMC7197612</ArticleId><ArticleId IdType="pubmed">32338708</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19. Final Report N Engl J Med. 2020;383(19):1813–1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>HV DTL, Gautret P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review. Eur J Clin Microbiol Infect Dis. 2021;40(1):13–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592450</ArticleId><ArticleId IdType="pubmed">33113040</ArticleId></ArticleIdList></Reference><Reference><Citation>Elzein F, Ibrahim A, Alshahrani F, et al. Reinfection, recurrence, or delayed presentation of COVID-19? Case series and review of the literature. J Infect Public Health. 2021;14(4):474–477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834000</ArticleId><ArticleId IdType="pubmed">33743368</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki M, Mitsutake K, Shimizu A, et al. Ensitrelvir improved SARS-CoV-2 viral titers of COVID-19 patients refractory to remdesivir World. J Clin Med Res. 2023;3(1):27–31.</Citation></Reference><Reference><Citation>Seki M, Hashimoto K, Kondo N, Ohya Y, Kotajima F, Mitsutake K. Sequential Treatment by Antiviral Drugs Followed by Immunosuppressive Agents for COVID-19 Patients with Hematological Malignancy. Infect Drug Resist. 2022;15:7117–7124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9733686</ArticleId><ArticleId IdType="pubmed">36506836</ArticleId></ArticleIdList></Reference><Reference><Citation>Puyuelo A F-CA, Martín-Buitrago L N. Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: an age-matched cohorts study. Clin Infect Pract. 2022;13:100137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8843327</ArticleId><ArticleId IdType="pubmed">35187467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcri C, Dentone C, Mikulska M, et al. The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study. Open Forum Infect Dis. 2021;8(11):ofab217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135455</ArticleId><ArticleId IdType="pubmed">34796242</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormazabal Vélez I, Induráin Bermejo J, Espinoza Pérez J, Imaz Aguayo L, Delgado Ruiz M, García-Erce JA. Two patients with rituximab associated low gamma globulin levels and relapsed covid-19 infections treated with convalescent plasma. Transfus Apher Sci. 2021;60(3):103104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894088</ArticleId><ArticleId IdType="pubmed">33637467</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschini E, Pellegrino M, Todisco V, et al. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. Infection. 2023;51(5):1577–1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10115373</ArticleId><ArticleId IdType="pubmed">37076752</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a Phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985–996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9173721</ArticleId><ArticleId IdType="pubmed">35688164</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Safety KR. Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. Antimicrob Ag Chem. 2022;66(10):e0063222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9578392</ArticleId><ArticleId IdType="pubmed">36094202</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukae H, Yotsuyanagi H, Ohmagari N, et al. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: results of the Phase 2a Part. Antimicrob Ag Chem. 2022;66(10):e0069722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9578433</ArticleId><ArticleId IdType="pubmed">36098519</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: the Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. Clin Infect Dis. 2023;76(8):1403–1411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10110269</ArticleId><ArticleId IdType="pubmed">36477182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397–1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikulska M, Sepulcri C, Dentone C, et al. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. Clin Infect Dis. 2023;77(2):280–286.</Citation><ArticleIdList><ArticleId IdType="pubmed">36976301</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Valtanen P, Hope CM, Masavuli MG, et al. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Rep Med. 2022;3(6):100651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110310</ArticleId><ArticleId IdType="pubmed">35654046</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>